Jaktinib Displays Significant Benefit Vs Hydroxyurea in Intermediate-2/High-Risk Myelofibrosis
June 10th 2023Patients with intermediate-2 or high-risk myelofibrosis who received the novel JAK/ACVR1 inhibitor jaktinib experienced a statistically significant improvement in the proportion of patients with a spleen-volume reduction of at least 35% from baseline at week 24 vs those who were treated with hydroxyurea.
Read More
A2B530 Harnesses Unique Mechanism of Action to Integrate CAR T in Solid Tumors
June 8th 2023Looking to replicate the impressive findings with CAR T-cell therapies observed in patients with hematologic malignancies, investigators have initiated the BASECAMP-1 trial with the hope of identifying patients with advanced solid tumors who will be suitable candidates for treatment in the EVEREST trial.
Read More
Trastuzumab Deruxtecan Elicits Responses in Difficult-To-Treat HER2+ Solid Tumors
June 5th 2023Fam-trastuzumab deruxtecan-nxki demonstrated clinically meaningful activity across a wide range of HER2 expressing solid tumors, including hard-to-treat tumors, according to findings from the phase 2 DESTINY-PanTumor02 trial.
Read More
Imetelstat Prolongs Transfusion Independence, Increases Hemoglobin in R/R MDS
June 2nd 2023Treatment with the first-in-class direct and competitive telomerase inhibitor imetelstat resulted in statistically significant and clinically meaningful efficacy in patients with heavily transfusion dependent, non-del(5q) lower-risk myelodysplastic syndrome that is relapsed or refractory to erythropoiesis stimulating agents, according to findings from the phase 3 IMerge trial.
Read More
Addition of Ribociclib to Endocrine Therapy Provides iDFS Benefit in HR+/HER2– Early Breast Cancer
June 2nd 2023Treatment with ribociclib plus endocrine therapy led to a statistically and clinically meaningful improvement in invasive disease-free survival among patients with hormone receptor–positive/HER2-negative early breast cancer compared with endocrine therapy alone, meeting the primary end point of the phase 3 NATALEE trial.
Read More
Novel CDK9 Inhibitor Looks to Expand Options in MYC-Amplified Solid Tumors and Non-Hodgkin Lymphoma
May 31st 2023Investigators are aiming to add another agent to the treatment armamentarium for patients with relapsed or refractory solid tumors, as well as those with non-Hodgkin lymphoma, with the development of KB-0742, a CDK9 inhibitor.
Read More
Latinx Patients Highlight Barriers to Tumor Genomic Profiling for Cancer
May 29th 2023Latinx patients with cancer had a low rate of tumor genomic profiling, partially due to structural and cultural barriers, according to findings from a qualitative study presented during the 5th Annual Regional SPEECH Conference and Retreat.
Read More
SPEECH Conference Highlights Multiplicity of Ongoing Efforts in Cancer Care Equity
May 23rd 2023Young investigators, fellows, and medical students recently gathered at the Temple University Lewis Katz School of Medicine in Philadelphia, Pennsylvania, to network and share exciting research aimed at addressing disparities in the dissemination of cancer care at the 5th Annual Regional Synergistic Partnership for Enhancing Equity in Cancer Health Conference and Retreat.
Read More
Encorafenib Plus Cetuximab/Binimetinib Displays Activity, Safety in BRAF V600E–mutant mCRC
May 17th 2023Triplet therapy consisting of encorafenib, cetuximab, and binimetinib demonstrated activity and manageable safety as first-line treatment for patients with BRAF V600E–mutated metastatic colorectal cancer.
Read More
EVEREST-1 Trial Seeks to Bring HLA-A*02-directed CAR T to Patients With Solid Tumors
May 16th 2023The upcoming phase 1/2 EVEREST-1 trial, where the novel CAR T-cell therapy A2B530 will be evaluated in patients with solid tumors, aims to push progress for one-and-done engineered therapies in this space.
Read More
mRNA Vaccine Autogene Cevumeran Plus Atezolizumab and Chemotherapy Displays Early Efficacy in PDAC
May 12th 2023Adjuvant treatment with the individualized RNA neoantigen vaccine autogene cevumeran in combination with atezolizumab and chemotherapy induced notable T-cell activity that could be correlated with delayed recurrence in patients with pancreatic ductal adenocarcinoma.
Read More
GD2-CART01 Elicits Clinical Activity, Tolerability in Pediatric R/R Neuroblastoma
May 8th 2023The investigational CAR T-cell therapy GD2-CART01 showed preliminary antitumor activity and safety in pediatric patients with relapsed or refractory high-risk neuroblastoma, according to data from a phase 1/2 trial.
Read More
Treatment with the androgen receptor inhibitor enzalutamide plus leuprolide led to a significant reduction in the risk of metastasis or death compared with placebo plus leuprolide in patients with nonmetastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence.
Read More
FDA Panel Votes Proposed Olaparib/Abiraterone Indication Should Be Restricted to BRCA-Mutant mCRPC
April 28th 2023In an 11-to-1 vote, the FDA’s Oncologic Drugs Advisory Committee voted that the proposed indication of olaparib in combination with abiraterone acetate and prednisone or prednisolone for the initial treatment of patients with metastatic castration-resistant prostate cancer should be restricted to those whose tumors harbor a BRCA mutation.
Read More
BASECAMP-1 Aims to Identify Patients Eligible for Treatment With Novel CAR T-Cell Agent
April 20th 2023Looking to replicate the impressive findings with CAR T-cell therapies observed in patients with hematologic malignancies, investigators have initiated the BASECAMP-1 trial, with the hope of identifying patients with advanced solid tumors who will be suitable candidates for treatment in a subsequent trial evaluating the investigational agent A2B530.
Read More
CYCLONE 1 Misses Primary End Point But Abemaciclib Shows Activity in mCRPC
April 18th 2023Although the phase 2 CYCLONE 1 trial did not meet its primary end point of overall response rate, treatment with abemaciclib did demonstrate clinical activity among patients with metastatic castration-resistant prostate cancer.
Read More
HECTOR Deep Learning Model Shows Predictability for Distant Recurrence Risk in Endometrial Cancer
April 18th 2023A deep learning risk prediction model was able to accurately identify patients with endometrial cancer at low and high risk of distant recurrence, according to data presented during the 2023 AACR Annual Meeting.
Read More
NICE Guidance Supports Olaparib Use in BRCA-Mutant Breast, Prostate Cancer
April 7th 2023The National Institute for Health and Care Excellence announced final draft guidance recommending the PARP inhibitor olaparib for patients with HER2-negative, high-risk early breast cancer harboring a BRCA1/2 mutation, as well as for those with previously treated hormone-relapsed metastatic prostate cancer with a BRCA1/2 mutation.
Read More
Rapid Advances Shake Up Treatment Considerations in ALL, CML, AML
April 6th 2023Elias Jabbour, MD; Harry Paul Erba, MD, PhD; Anjali Advani, MD; and Sameem Abedin, MD, discuss key updates pertaining to the leukemia treatment landscape that were presented at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition.
Read More